Abstract

The presence of fetal DNA in maternal plasma has allowed the development of strategies for noninvasive prenatal diagnosis (1). However, because fetal DNA in maternal plasma circulates among a background of maternal DNA, strategies for noninvasive prenatal diagnosis with applications of fetal DNA in maternal plasma have been confined to the detection of autosomal dominant, paternally inherited genetic traits, such as fetal gender (for sex-linked disorders) (1), rhesus D (2)(3), myotonic dystrophy (4), and achondroplasia (5). Using congenital adrenal hyperplasia (CAH) as a model system, we present a strategy for the noninvasive prenatal exclusion of an autosomal recessive condition through the detection of fetal DNA in maternal plasma. The approach described in this study may potentially be applicable to other autosomal recessive conditions. More than 90% of cases of CAH are a result of deficiency of 21-hydroxylase, an enzyme of the adrenal gland involved in the synthesis of glucocorticoids and mineralocorticoids. 21-Hydroxylase is encoded by CYP21 , a MHC class III gene located on chromosome 6p21.3. Most mutations causing 21-hydroxylase deficiency are caused by either gene deletions or gene conversions, whereby deleterious mutations are transferred from the nearby pseudogene, CYP21P , which shares 98% homology with CYP21 (6). Consequent to profound deficiency or the complete absence of activity of 21-hydroxylase, severe forms of CAH manifest as salt-wasting attributable to impaired synthesis of mineralocorticoids and glucocorticoids. In addition, the excess buildup of metabolic precursors causes excessive androgen production, leading to virilization of female fetuses (6). Hence, dexamethasone therapy is customarily prescribed prenatally to prevent in utero virilization of an affected female fetus through suppression of the excessive …

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call